Does Whole Blood Adsorber During CPB Reduce Vasoactive Drugs Postoperatively in Endocarditis Patients Undergoing Valve Surgery?

Not Applicable

Completed

• Conditions: Infective Endocarditis
• Interventions: Device: CytoSorb

• Registration Number: NCT03945708
• Lead Sponsor: Emma Hansson

Brief Summary

The study aims to investigate the effect of addition of an adsorber during cardio pulmonary bypassin patients with infective endocarditis undergoing valve surgery, and if it will decrease the use of vasoactive drugs postoperatively.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-05-09
• Study First Submitted QC: 2019-05-09
• Study First Posted: 2019-05-10
• Study Start: 2019-05-15
• Primary Completion: 2020-12-31
• Study Completion: 2020-12-31
• Status Verified: 2021-09
• Last Update Submitted: 2021-09-20
• Last Update Posted: 2021-09-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Infected endocarditis patients undergoing heart valve surgery.
2. Age over 18 years.

Exclusion Criteria

1 Declines participation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment	CytoSorb	Addition of whole blood adsorber to CPB circuit

Primary Outcome Measures

Name	Time	Method
Use of vasoactive substances	48 hours	Use of norepinephrine in ICU

Secondary Outcome Measures

Name	Time	Method
Blood transfusions	48 hours	Transfusion of red blood cells, plasma and platelets
Chest tube bleeding	48 hours	Chest tube output in ml
Milrinone use	48 hours	Amount of milrinone used 24 and 48 hours postoperatively

Trial Locations

Locations (1)

Sahlgrenska University Hospital; 🇸🇪 Gothenburg, Sweden